$ICPT Intercept has excellent liquid asset/cash to funded debt position. Excellent forecasted sales in relation to mkt cap and cash. With profitable in mkt asset in PBC/ great forecasted sales and a large amount of research and development costs which will be cut significantly with Phase 3 trial commencements this company is undervalued on in mkt assets and balance sheet strength alone. Excellent entry; any price below $20 WITHOUT NASH considered is excellent price imo.
12
17
17 Likes